Literature DB >> 7626045

The effect of hepatocyte growth factor on the behaviour of osteoclasts.

K Fuller1, J Owens, T J Chambers.   

Abstract

Hepatocyte growth factor (HGF) stimulates the growth, motility and morphogenesis of a variety of cell types, including hemopoietic progenitors. We found that HGF is a potent inhibitor of bone resorption by isolated rat osteoclasts. However, in the presence of the osteoblastic cell line UMR 106, it stimulated osteoclastic resorption. HGF also increased osteoclastic motility and spread area, over a similar concentration range. We detected no effect on osteoclast formation or survival. Our data suggest that HGF may be involved in the recruitment of osteoclasts to sites of bone resorption, but that during migration resorptive functions are suppressed. Once on resorptive sites, the osteoclast response to HGF is modulated by osteoblastic cells and the bone resorptive activity of osteoclasts may be stimulated accordingly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7626045     DOI: 10.1006/bbrc.1995.1974

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases.

Authors:  A Lochter; M J Bissell
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

2.  Hepatocyte growth factor administration increases bone soluble phosphate and alters bone chemical structure in diabetic hypertensive rats.

Authors:  Kamal Awad; Natasha G Boyes; Ramlah Iqbal; Mohamed Ahmed; Adel Mohamed; Pranesh Aswath; Corey R Tomczak; Venu Varanasi
Journal:  J Mater Res       Date:  2021-07-23       Impact factor: 2.909

3.  Effect of semisynthetic extracellular matrix-like hydrogel containing hepatocyte growth factor on repair of femoral neck defect in rabbits.

Authors:  Pengfei Liu; Lin Guo; Lanfeng Huang; Dewei Zhao; Ruixin Zhen; Xiaoning Hu; Xiaolin Yuan
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  Lipoteichoic acid and interleukin 1 stimulate synergistically production of hepatocyte growth factor (scatter factor) in human gingival fibroblasts in culture.

Authors:  A Sugiyama; R Arakaki; T Ohnishi; N Arakaki; Y Daikuhara; H Takada
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

Review 5.  Role of hepatocyte growth factor and its receptor c-met in multiple myeloma.

Authors:  C Seidel; M Børset; H Hjorth-Hansen; A Sundan; A Waage
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

6.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Jiri Minarik; Tomas Pika; Jaroslav Bacovsky; Pavla Petrova; Katerina Langova; Vlastimil Scudla
Journal:  ScientificWorldJournal       Date:  2012-04-26

8.  Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones.

Authors:  M T Engsig; Q J Chen; T H Vu; A C Pedersen; B Therkidsen; L R Lund; K Henriksen; T Lenhard; N T Foged; Z Werb; J M Delaissé
Journal:  J Cell Biol       Date:  2000-11-13       Impact factor: 10.539

9.  High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.

Authors:  Hidenori Fujita; Akira Gomori; Yayoi Fujioka; Yuki Kataoka; Kenji Tanaka; Akihiro Hashimoto; Takamasa Suzuki; Kenjiro Ito; Tomonori Haruma; Hiromi Yamamoto-Yokoi; Naomoto Harada; Motomu Sakuragi; Nobuyuki Oda; Kenichi Matsuo; Masaki Inada; Kazuhiko Yonekura
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.